Trevi Therapeutics (TRVI) Revenue & Revenue Breakdown
Trevi Therapeutics Revenue Highlights
Trevi Therapeutics Revenue by Period
Trevi Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | - |
Trevi Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Trevi Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $176.00K | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | - |
Trevi Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Trevi Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CHRS | Coherus BioSciences | $257.24M | $64.98M |
| SPRO | Spero Therapeutics | $96.73M | $10.20M |
| FHTX | Foghorn Therapeutics | $34.16M | $6.89M |
| SQZ | SQZ Bio | $21.03M | - |
| SEER | Seer | $16.66M | $3.07M |
| BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
| CUE | Cue Biopharma | $5.49M | $1.72M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| LIFE | aTyr Pharma | $353.00K | $235.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| CGEM | Cullinan Oncology | - | - |
| CCCC | C4 Therapeutics | - | - |
| ANTX | AN2 Therapeutics | - | - |
| GRCL | Gracell Bio | - | - |
| BCAB | BioAtla | - | - |
| TARA | Protara Therapeutics | - | - |
| CYT | Cyteir Therapeutics | - | - |
| TRVI | Trevi Therapeutics | - | - |
| NLTX | Neurogene | - | - |
| PRLD | Prelude Therapeutics | - | - |
| ORIC | ORIC Pharmaceuticals | - | - |
TRVI Revenue FAQ
What is Trevi Therapeutics’s yearly revenue?
Trevi Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021. TRVI's yearly revenue for 2021 was $0, representing an increase of 100.00% compared to 2020.
What is Trevi Therapeutics’s quarterly revenue?
Trevi Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). TRVI's quarterly revenue for Q4 2023 was $176K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Trevi Therapeutics’s revenue growth rate?
Trevi Therapeutics's revenue growth rate for the last 3 years (2021-2023) was 0%, and for the last 5 years (2019-2023) was 0%.